FDA approved Bristol Myers Squibb's iberdomide (Zenbexus) for relapsed/refractory multiple myeloma at $29,500/cycle, used with Darzalex and dexamethasone.
August 13, 2026 05:19 PM EDT
FDA approves Bristol Myers’ multiple myeloma successor
The FDA has granted accelerated approval for a Bristol Myers Squibb pill called iberdomide for patients with multiple myeloma that’s returned or stopped responding to …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Bristol Myers Squibb Gets FDA Nod For Myeloma Treatment - Bristol-Myers Squibb (NYSE:BMY)
Zenbexus-led combination nabs FDA’s first CELMoD therapy approval in multiple myeloma
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
FDA Approves First CELMoD Drug for Multiple Myeloma
Bristol Myers wins ‘milestone’ FDA approval of myeloma drug acquired from Celgene
FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
SFDA becomes first regulatory authority globally to approve registration of 'ZENBEXUS' to treat multiple myeloma in adults
Bristol Myers Squibb secures FDA approval for Zenbexus (iberdomide), marking the first CELMoD therapy approval.
FDA accepts Bristol Myers Squibb's mezigdomide NDA for relapsed multiple myeloma, with a PDUFA decision due May 13, 2027.
The FDA has granted accelerated approval to the first cereblon E3 ligase modulation therapy for patients with multiple…
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab…
Iberdomide indicated as part of combination regimen for relapsed or refractory disease
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed…
